Gufic Biosciences Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Pranav Choksi

Algemeen directeur

₹4.4m

Totale compensatie

Percentage CEO-salaris	99.1%
Dienstverband CEO	20.4yrs
Eigendom CEO	7.2%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	9.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Pranav Choksi's beloning veranderd ten opzichte van Gufic Biosciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹849m
Jun 30 2024	n/a	n/a	₹864m
Mar 31 2024	₹4m	₹4m	₹861m
Dec 31 2023	n/a	n/a	₹842m
Sep 30 2023	n/a	n/a	₹823m
Jun 30 2023	n/a	n/a	₹793m
Mar 31 2023	₹2m	₹2m	₹797m
Dec 31 2022	n/a	n/a	₹819m
Sep 30 2022	n/a	n/a	₹826m
Jun 30 2022	n/a	n/a	₹857m
Mar 31 2022	₹2m	₹2m	₹958m
Dec 31 2021	n/a	n/a	₹884m
Sep 30 2021	n/a	n/a	₹829m
Jun 30 2021	n/a	n/a	₹769m
Mar 31 2021	₹6m	₹2m	₹442m
Dec 31 2020	n/a	n/a	₹305m
Sep 30 2020	n/a	n/a	₹243m
Jun 30 2020	n/a	n/a	₹123m
Mar 31 2020	₹5m	₹2m	₹227m
Dec 31 2019	n/a	n/a	₹243m
Sep 30 2019	n/a	n/a	₹232m
Jun 30 2019	n/a	n/a	₹249m
Mar 31 2019	₹2m	₹2m	₹219m
Dec 31 2018	n/a	n/a	₹164m
Sep 30 2018	n/a	n/a	₹168m
Jun 30 2018	n/a	n/a	₹164m
Mar 31 2018	₹2m	₹2m	₹165m

Compensatie versus markt: De totale vergoeding ($USD 52.46K ) Pranav } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 272.27K ).

Compensatie versus inkomsten: De vergoeding van Pranav is het afgelopen jaar met meer dan 20% gestegen.

CEO

Pranav Choksi (41 yo)

20.4yrs

Tenure

₹4,432,332

Compensatie

Mr. Pranav Jayesh Choksi has been an Executive Whole Time Director of Gufic Biosciences Ltd. since June 25, 2004 and serves as its Chief Executive Officer. Mr. Choksi serves as Chief Executive Officer & Wh...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jayesh Choksi	Chairman & MD	25.3yrs	₹4.82m	24.62% ₹ 10.1b
Pranav Choksi	CEO & Whole Time Director	20.4yrs	₹4.43m	7.25% ₹ 3.0b
Pankaj Gandhi	Whole-Time Director	11.3yrs	₹1.74m	geen gegevens
Gopal Daptari	Independent Director	8yrs	₹60.00k	geen gegevens
Anu Aurora	Independent Director	4.9yrs	₹70.00k	geen gegevens
Kamal Seth	Independent Director	less than a year	geen gegevens	geen gegevens

9.6yrs

Gemiddelde duur

67.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 509079 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.6 jaar).

Gufic Biosciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Gufic Biosciences Limited Announces Cessation of Shreyas Patel as Independent Director and New Composition of Committees

Gufic Biosciences Limited, Annual General Meeting, Sep 25, 2024

Gufic Biosciences Limited Announces Resignation of Bal Ram Singh as Non-Executive and Non-Independent Director

Gufic Biosciences Limited Announces Cessation of Rabi Sahoo as Independent Director and Chairman of Stakeholders Relationship Committee and Member of Audit Committee

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

Recent updates

Second quarter 2025 earnings released: EPS: ₹2.17 (vs ₹2.39 in 2Q 2024)

Gufic Biosciences Limited to Report Q2, 2025 Results on Nov 14, 2024

Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2024

Gufic Biosciences Limited Announces Cessation of Shreyas Patel as Independent Director and New Composition of Committees

Dividend of ₹0.10 announced

Gufic Biosciences Limited, Annual General Meeting, Sep 25, 2024

First quarter 2025 earnings released: EPS: ₹2.08 (vs ₹2.13 in 1Q 2024)

Gufic Biosciences Limited Announces Resignation of Bal Ram Singh as Non-Executive and Non-Independent Director

Gufic Biosciences Limited to Report Q1, 2025 Results on Aug 14, 2024

Gufic Biosciences Limited Announces Cessation of Rabi Sahoo as Independent Director and Chairman of Stakeholders Relationship Committee and Member of Audit Committee

Investor sentiment improves as stock rises 19%

Gufic Biosciences Limited Proposes Recommendation of Final Dividend for the Financial Year 2023-24

Full year 2024 earnings released: EPS: ₹8.74 (vs ₹8.22 in FY 2023)

Third quarter 2024 earnings released: EPS: ₹2.23 (vs ₹2.10 in 3Q 2023)

Second quarter 2024 earnings released: EPS: ₹2.39 (vs ₹2.09 in 2Q 2023)

Gufic Biosciences Limited announced that it has received INR 999.9 million in funding from Motilal Oswal Financial Services Limited

Upcoming dividend of ₹0.10 per share

Gufic Biosciences Limited to Report Q2, 2024 Results on Nov 14, 2023

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

New minor risk - Shareholder dilution

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

First quarter 2024 earnings released: EPS: ₹2.13 (vs ₹2.17 in 1Q 2023)

Gufic Biosciences Limited to Report Q1, 2024 Results on Aug 11, 2023

Investor sentiment improves as stock rises 18%

Gufic Biosciences Limited Recommends Dividend for the Financial Year Ended March 31, 2023

Full year 2023 earnings released: EPS: ₹8.22 (vs ₹9.89 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹2.10 (vs ₹2.17 in 3Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹0.10 per share

First quarter 2023 earnings released: EPS: ₹2.17 (vs ₹3.22 in 1Q 2022)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Gufic Biosciences Limited, Annual General Meeting, Sep 02, 2022

Gufic Biosciences Limited to Report Q1, 2023 Results on Aug 11, 2022

Investor sentiment improved over the past week

Gufic Biosciences Limited Launches New Drug Delivery System

Full year 2022 earnings released: EPS: ₹9.89 (vs ₹4.56 in FY 2021)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Now 21% undervalued

Gufic Biosciences Limited Receives Permission from CDSCO to Manufacture and Sale Isavuconazonium Sulfate API and Finished Formulation Isavuconazole for Injection 200 Mg/Vial

Now 21% undervalued

Gufic Biosciences Limited Receives DCGI Nod for Thymosin Alpha - 1

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹2.41 (vs ₹2.10 in 2Q 2021)

Upcoming dividend of ₹0.10 per share

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹4.56 (vs ₹2.94 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: ₹109

Third quarter 2021 earnings released: EPS ₹1.69 (vs ₹0.90 in 3Q 2020)

Gufic Biosciences Limited to Report Q3, 2021 Results on Feb 08, 2021

New 90-day high: ₹132

Second quarter 2021 earnings released: EPS ₹2.10

Market bids up stock over the past week

Market bids up stock over the past week

New 90-day high: ₹103

Upcoming Dividend of ₹0.05 Per Share

First quarter earnings released

Full year earnings released - EPS ₹2.94

Gufic Biosciences Limited to Report Q4, 2020 Results on Jul 31, 2020

Analyse CEO-vergoeding

CEO